Dr. Khalid Shah, a renowned scientist from Kashmir, has introduced a “safety switch” mechanism to eliminate cancer-killing cells after their therapeutic role is complete.
This innovation, published in the Journal of Clinical Investigation on January 16, enhances the safety of cell-based therapies while boosting the immune system to combat tumors.
Laboratory models showed improved survival rates and tumor suppression.
Building on his earlier work, where he engineered cancer cells to destroy glioblastoma—the deadliest brain cancer—Dr. Shah’s latest development addresses safety concerns in cell-based treatments.
His prior therapies utilized tumor cells to deliver targeted agents, overcoming challenges in drug delivery.
Dr. Shah, currently Vice Chairman of Research at Harvard Medical School, has pioneered two therapeutic approaches: an “off-the-shelf” method using pre-engineered cells and an “autologous” technique involving CRISPR-modified cells.
His research sets the stage for safer, personalized treatments across various cancers.
With over 15 patents and global recognition in journals like Nature Neuroscience, Dr. Shah’s contributions offer hope for glioblastoma patients and beyond, marking a significant step forward in oncology.